CPRX
Catalyst Pharmaceuticals, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website catalystpharma.com
- Employees(FY) 82
- ISIN US14888U1016
Performance
-0.33%
1W
-0.56%
1M
-0.37%
3M
+42.08%
6M
+26.53%
YTD
+48.74%
1Y
Profile
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Technical Analysis of CPRX 2024-12-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-18 09:40
- 2024-12-17 19:00
CPRX: What does Argus have to say about CPRX?(Argus Research)
- 2024-12-16 08:03
- 2024-12-15 19:03
- 2024-12-11 15:06
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating(Investor's Business Daily)
- 2024-12-10 19:00
CPRX: What does Argus have to say about CPRX?(Argus Research)
- 2024-12-06 11:31
- 2024-12-03 19:00
CPRX: What does Argus have to say about CPRX?(Argus Research)
- 2024-12-03 13:27
- 2024-12-02 14:21
- 2024-11-27 09:50
- 2024-11-26 19:00
CPRX: Raising target price to $23.00(Argus Research)
- 2024-11-25 08:03
- 2024-11-24 19:03
- 2024-11-19 08:03
- 2024-11-18 19:03
- 2024-11-15 09:45
- 2024-11-13 08:03
- 2024-11-13 05:48
- 2024-11-12 19:03
- 2024-11-12 19:00
CPRX: Raising target price to $24.00(Argus Research)
- 2024-11-11 14:06
Vericel Stock Sees RS Rating Shoot Higher(Investor's Business Daily)
- 2024-11-10 18:00
- 2024-11-08 06:50
- 2024-11-07 09:15
- 2024-11-06 18:00
- 2024-11-06 17:25
- 2024-11-06 16:22
Catalyst: Q3 Earnings Snapshot(Associated Press Finance)
- 2024-11-06 16:12
- 2024-11-06 11:40
Page 1 of 9
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.